Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians

Attention deficit/hyperactivity disorder (ADHD) is a common disorder and a plethora of new data has been published from clinical trials and national epidemiological databases in the last three years. In the United Kingdom Atomoxetine is currently the only licensed non-stimulant medication. As part o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushe, Chris J., Savill, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663616/
https://www.ncbi.nlm.nih.gov/pubmed/23861650
http://dx.doi.org/10.4137/JCNSD.S4391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663616/
https://www.ncbi.nlm.nih.gov/pubmed/23861650
http://dx.doi.org/10.4137/JCNSD.S4391

Ejemplares similares